Repare Therapeutics Inc(RPTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.69 | Insider Own | 19.56% | Shs Outstand | 43.0M | Perf Week | 2.71% |
| Market Cap | 0.11B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 34.7M | Perf Month | 3.92% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 19.91% | Short Float | 1.26% | Perf Quarter | 35.2% |
| Income | -0.07B | P/S | 9.62 | EPS this Y | - | Inst Trans | - | Short Ratio | 0.39 | Perf Half Y | 67.72% |
| Sales | 0.01B | P/B | 0.99 | EPS next 5Y | - | ROA | -43.35% | Short Interest | 0.44M | Perf YTD | 1.92% |
| Book/sh | 2.68 | P/C | 1.01 | EPS past 3/5Y | 10.94% -21.89% | ROE | -49.78% | 52W High | -0.38% ($2.66) | Perf Year | 117.21% |
| Cash/sh | 2.61 | P/FCF | - | Sales past 3/5Y | 91.62% - | ROIC | -62.71% | 52W Low | 197.75% ($0.89) | Perf 3Y | -77.58% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 14.58% | Gross Margin | 76.85% | Volatility(W/M) | 1.33% 1.63% | Perf 5Y | -93.34% |
| Dividend TTM | - | EV/Sales | 0.17 | Sales Y/Y TTM | -82.16% | Oper. Margin | -664.14% | ATR (14) | 0.05 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.71 | EPS Q/Q | 109.34% | Profit Margin | -608.26% | RSI (14) | 73.22 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.71 | Sales Q/Q | - | SMA20 | 2.62% ($2.58) | Beta | 0.99 | Target Price | $3 |
| Payout | - | Debt/Eq | 0 | Earnings | 2025/11/14 | SMA50 | 13.82% ($2.33) | Rel Volume | 0 | Prev Close | $2.65 |
| Employees | 129 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 134.31% 132.4% | SMA200 | 51.82% ($1.75) | Avg Volume(3M) | 1.11M | Price | $2.65 |
| IPO | 2020/6/19 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
🧬 Repair Therapeutics (RPTX) is a U.S. clinical-stage biotech that uses its proprietary CRISPR gene-editing-based screening platform to identify cancer-cell-specific genetic vulnerabilities and develop innovative precision oncology drugs that selectively target them.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
RPTX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $962. Peers typically go for $192.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.3%. The S&P 500 did +57% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.9%.
Tap to view numbers
It ranks #346 of 598 in the industry
Based on market cap of $114M.
ENGN#342 enGene Therapeutics Inc $117M PER - 
OKUR#343 OnKure Therapeutics Inc $116M PER - 
NERV#344 Minerva Neurosciences Inc $116M PER - 
VYGR#345 Voyager Therapeutics Inc $115M PER - RPTX#346 Repare Therapeutics Inc $114M PER - 
FAQ
What kind of company is RPTX?
RPTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RPTX?
The market cap of RPTX is approximately $114M, ranking 4,407 within its sector.
What is the 52-week high and low for RPTX?
RPTX has recorded a 52-week high of $2.66 and a low of $0.89.
